<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of thrombocytopenia in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of thrombocytopenia in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of thrombocytopenia in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Neunert, MD, MSCS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thrombocytopenia is defined as a platelet count of &lt;150,000/microL. It is clinically suspected when there is a history of easy bruising or bleeding, or it may present as an incidental finding during routine evaluation or during investigations performed for other reasons.</p><p>Causes of thrombocytopenia in children will be reviewed here. Causes of neonatal thrombocytopenia differ somewhat and are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology"</a>.)</p><p>The approach to evaluating a child with unexplained thrombocytopenia and/or bleeding symptoms and the details of specific causes of thrombocytopenia (eg, immune thrombocytopenia, leukemia, aplastic anemia) are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>A variety of schemes have been used in classifying the causes of thrombocytopenia, including categorization based on:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet size – Large (mean platelet volume [MPV] &gt;11 fL), normal (MPV 7 to 11 fL), and small (MPV &lt;7 fL)</p><p class="bulletIndent1"><span class="glyph">●</span>Mode of acquisition – Acquired or inherited</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanism – Increased destruction (including sequestration and pooling of platelets), dilutional, or decreased production of platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Degree of the thrombocytopenia – Mild to moderate thrombocytopenia (&gt;20,000/microL) or severe thrombocytopenia (&lt;20,000/microL)</p><p></p><p>This topic review will primarily use a categorization based on mechanism of thrombocytopenias  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 1</a>). Classification by platelet size is also clinically useful, especially for differentiating the various inherited platelet disorder syndromes  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 2</a>). Historical platelet counts (if available) and detailed family history can be helpful to distinguish inherited and acquired thrombocytopenias.</p><p class="headingAnchor" id="H3"><span class="h1">PLATELET DESTRUCTION</span><span class="headingEndMark"> — </span>The destructive mechanisms resulting in thrombocytopenia in children include:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune-mediated destruction</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet activation and consumption</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical platelet destruction</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet sequestration and trapping</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Immune-mediated causes</span><span class="headingEndMark"> — </span>Immune-mediated processes are among the most common causes of thrombocytopenia. Autoantibodies, drug-dependent antibodies, or alloantibodies mediate platelet destruction through interaction with platelet membrane antigens or by forming immune complexes, which can bind to reticuloendothelial cell Fc receptors, leading to platelet clearance from the circulation. The most common immune-mediated thrombocytopenia in children is immune thrombocytopenia (ITP).</p><p>In neonates, alloimmune thrombocytopenia is an important cause of thrombocytopenia that requires prompt recognition as it can be associated with intracranial hemorrhage. Neonatal alloimmune thrombocytopenia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Immune thrombocytopenia</span><span class="headingEndMark"> — </span>ITP is the most common acquired cause of thrombocytopenia in children. It can present at any age; peak incidence in childhood is between two and five years. Affected children may be asymptomatic but usually present with the sudden appearance of bruising and/or bleeding. ITP follows an antecedent viral illness in approximately one-half of cases; however, often no trigger is identified. Affected children are otherwise healthy appearing. The clinical manifestations, diagnosis, and management of ITP in children are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p>There is a small increased risk of developing ITP following live virus immunization, especially the measles, mumps, and rubella vaccine. In addition, vaccine-associated thrombocytopenia has been described as a rare side effect of the adenoviral coronavirus disease 2019 (COVID-19) vaccines. (See  <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">"Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis", section on 'Preceding illness or vaccination'</a> and  <a class="medical medical_review" href="/z/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/131333.html" rel="external">"COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)"</a>.)</p><p>Infrequently, other autoimmune-mediated cytopenias (most commonly, autoimmune hemolytic anemia) present coincidentally or sequentially with thrombocytopenia, a condition known as Evans syndrome [<a href="#rid1">1</a>]. ITP can also manifest as part of a systemic autoimmune or immune dysregulation disorder (secondary ITP). Secondary ITP can be highly refractory to standard ITP treatments but generally responds well to treatment of the primary disorder. It is especially important to consider an underlying immune disorder in children with Evans syndrome, as there is a high frequency of immune disorders in this population (up to 65 percent) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis", section on 'Evans syndrome'</a>.)</p><p>Examples of autoimmune disorders that can present with or develop ITP include (but are not limited to):</p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid antibody syndrome (see  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (see  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Hematologic'</a> and  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Laboratory findings'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crohn disease (see  <a class="medical medical_review" href="/z/d/html/5865.html" rel="external">"Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hepatitis (see  <a class="medical medical_review" href="/z/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune thyroid disease (see  <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence", section on 'Autoimmune thyroiditis'</a>)</p><p></p><p>Immune deficiency and/or dysregulation syndromes can also trigger ITP. Examples include (but are not limited to) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune lymphoproliferative syndrome (see  <a class="medical medical_review" href="/z/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common variable immunodeficiency (see  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CTLA-4 deficiency (see  <a class="medical medical_review" href="/z/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis", section on 'CTLA-4 haploinsufficiency with autoimmune infiltration (CHAI) disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DiGeorge syndrome (see  <a class="medical medical_review" href="/z/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wiskott-Aldrich syndrome (WAS) (see  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Drug-induced thrombocytopenia</span><span class="headingEndMark"> — </span>Drug-induced thrombocytopenia is typically caused by drug-dependent antibodies formed against a new antigen on the platelet surface created by drug binding to a platelet surface protein. Heparin-induced thrombocytopenia, which can be associated with severe thrombosis, is due to the formation of antibodies against a heparin-platelet factor 4 complex. This results in platelet activation leading to consumption of platelets and formation of thrombi. This condition is more common in adult patients and is relatively rare in children [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Unfractionated heparin'</a>.)</p><p>Other drugs that have been implicated in immune-mediated thrombocytopenia include <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproic acid</a>, <a class="drug drug_pediatric" data-topicid="12756" href="/z/d/drug information/12756.html" rel="external">quinine</a>, <a class="drug drug_pediatric" data-topicid="12755" href="/z/d/drug information/12755.html" rel="external">quinidine</a>, <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a>, and <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Platelet activation and consumption</span><span class="headingEndMark"> — </span>Thrombocytopenia due to platelet activation and consumption occurs in the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microangiopathic disorders</strong> – Microangiopathic disorders include disseminated intravascular coagulation and the thrombotic microangiopathies (TMAs, which include Shiga toxin-mediated hemolytic uremic syndrome [ST-HUS], compliment-mediated hemolytic uremic syndrome [CM-HUS], and thrombotic thrombocytopenic purpura [TTP]). In these disorders, thrombocytopenia occurs as a result of platelet activation, aggregation, and consumption. TMAs are characterized by abundant schistocytes on the peripheral smear  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 1</a>), anemia, neurologic changes (in TTP), and renal insufficiency (in ST-HUS and CM-HUS). In these conditions, the formation of microthrombi results in red cell shearing and end-organ damage. (See  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a> and  <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a>.)</p><p></p><p class="bulletIndent1">Hereditary TTP (Upshaw-Schulman syndrome) is a rare disorder due to a congenital absence of ADAMTS13, whereas acquired TTP results from antibody formation against ADAMTS13. In hereditary TTP, thrombocytopenia tends to be sporadic, occurring in acute episodes, usually with illness; hence, this disorder should be considered when mostly normal platelet counts are interspersed with transient, recurrent thrombocytopenia [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/101504.html" rel="external">"Hereditary thrombotic thrombocytopenic purpura (hTTP)"</a>.)</p><p></p><p>Rapid recognition of microangiopathic disorders is important as these represent a class of disorders with high morbidity and mortality, and prompt initiation of the correct management is essential. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major surgery or trauma</strong> – Thrombocytopenia is a common finding after major surgery or trauma. Low platelet counts in this setting result from acute blood loss, hemodilution, and consumption of platelets in maintaining hemostasis. The degree of thrombocytopenia is generally mild to moderate (50,000 to 100,000/microL). This is essentially a "normal" finding, and evaluation for other causes thrombocytopenia is generally not necessary if there are no signs of overt bleeding. Patients should be monitored to ensure platelet counts recover back to normal levels. Platelet transfusions in this setting should be reserved for patients with bleeding. The platelet count nadir typically occurs between one to four days after surgery, and counts usually increase back to baseline levels within one week to 10 days [<a href="#rid8">8,9</a>]. Additional evaluation may be warranted if the degree and/or duration of thrombocytopenia is atypical (platelet count &lt;20,000/microL or thrombocytopenia that persists beyond two weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kasabach-Merritt phenomenon</strong> – A more localized manifestation of coagulation activation and platelet trapping accounts for the thrombocytopenia found in individuals with Kasabach-Merritt phenomenon, which is a complication of kaposiform hemangioendotheliomas and tufted hemangiomas. (See  <a class="medical medical_review" href="/z/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.) </p><p></p><p class="bulletIndent1">In other vascular anomalies, patients can develop a localized intravascular coagulopathy which will similarly result in thrombocytopenia.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Mechanical destruction</span><span class="headingEndMark"> — </span>The use of extracorporeal therapies, such as extracorporeal membrane oxygenation, cardiopulmonary bypass, hemodialysis, and apheresis, is associated with mechanical destruction of platelets, which may result in thrombocytopenia and bleeding [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview", section on 'Complications'</a> and  <a class="medical medical_review" href="/z/d/html/134266.html" rel="external">"Extracorporeal life support in adults: Management of venovenous extracorporeal membrane oxygenation (V-V ECMO)", section on 'Thrombocytopenia'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Sequestration and trapping</span><span class="headingEndMark"> — </span>Sequestration and trapping of platelets occurs in hypersplenia and rare forms of von Willebrand disease (VWD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersplenism</strong> – Normally, approximately one-third of the platelet pool is sequestered in the spleen. In patients with hypersplenism, a greater proportion of platelets are sequestered, reducing the number of circulating platelets and often leading to thrombocytopenia. Leukopenia and anemia may also accompany a low platelet count. The platelet count in hypersplenism rarely falls below 50,000/microL. (See  <a class="medical medical_review" href="/z/d/html/5928.html" rel="external">"Approach to the child with an enlarged spleen"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VWD</strong> – Type 2B VWD and platelet-type VWD (also called "pseudo-VWD") may be associated with thrombocytopenia. In patients with these disorders, increased binding between larger von Willebrand factor multimers and platelets leads to the formation of small platelet aggregates, which are cleared from the circulation, resulting in a lower platelet count. The platelet aggregates may appear similar to large or giant platelets and can result in high mean platelet volume measurements by automated counters. (See  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Summary of VWD types'</a>.)</p><p></p><p class="headingAnchor" id="H2199189410"><span class="h1">DILUTIONAL</span><span class="headingEndMark"> — </span>Thrombocytopenia can result from dilution in the setting of massive transfusions, defined roughly as 40 mL/kg of red blood cells (RBCs) within 24 hours in pediatric patients. (See  <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Definitions and jargon'</a>.)</p><p>Pediatric patients rarely require massive transfusions, but they are occasionally required in patients with severe traumatic injuries and those undergoing surgical procedures with high bleeding risk. Massive transfusions can cause electrolyte abnormalities, hemodilution, and volume overload. They are associated with high risk of morbidity and mortality. Patients receiving large volumes of transfused RBCs can be expected to develop some degree of dilutional thrombocytopenia. This can be overcome by activation of a massive transfusion protocol which empirically provides platelet support (usually in a 1:1:1 ratio of platelets, fresh frozen plasma, and RBCs) or the use of whole blood. One concern over the use of whole blood, however, is the potential impact of whole blood storage on platelet function [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">"Massive blood transfusion", section on 'Approach to volume and blood replacement'</a>.) </p><p class="headingAnchor" id="H12"><span class="h1">IMPAIRED PLATELET PRODUCTION</span><span class="headingEndMark"> — </span>Decreased production of platelets may be due to:</p><p class="bulletIndent1"><span class="glyph">●</span>Suppression (ie, infection)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow infiltration </p><p class="bulletIndent1"><span class="glyph">●</span>Failure or a defect in megakaryocyte development and differentiation (nutritional deficiencies and inherited platelet disorders)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Thrombocytopenia due to infections (independent of disseminated intravascular coagulation) is usually caused by bone marrow suppression [<a href="#rid12">12-14</a>]. In some cases, the low platelet count also can be due in part to an immune-mediated process.</p><p>Infection-associated thrombocytopenia can occur with many different pathogens; infectious agents that are commonly implicated include Epstein-Barr virus, cytomegalovirus, parvovirus, and rickettsia. (See  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">"Overview of cytomegalovirus infections in children"</a> and  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever"</a>.)</p><p>In patients with COVID-19, thrombocytopenia can be seen during the acute infection or as a postinfectious immune-mediated complication. (See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a> and  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p>Thrombocytopenia is a common finding in HIV-infected patients. The mechanisms underlying HIV-related thrombocytopenia are complex and involve both immune-mediated platelet destruction and impaired production. (See  <a class="medical medical_review" href="/z/d/html/6679.html" rel="external">"HIV-associated cytopenias", section on 'General concepts'</a>.)</p><p>Thrombocytopenia is a common finding in patients with bacterial sepsis. In this setting, thrombocytopenia is often multifactorial with components of marrow suppression, consumption due to disseminated intravascular coagulation and inflammatory response, and/or drug-induced. (See  <a class="medical medical_review" href="/z/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Laboratory studies'</a>.)</p><p>Data on time to recovery of a normal platelet count from most commonly acquired infections are sparse, but in the otherwise healthy child, the thrombocytopenia is transient, with recovery within a period of weeks.</p><p class="headingAnchor" id="H2633276286"><span class="h2">Nutritional deficiencies</span><span class="headingEndMark"> — </span>The following nutritional deficiencies have been associated with thrombocytopenia:</p><p class="bulletIndent1"><span class="glyph">●</span>Folate and vitamin B12 deficiencies can impair bone marrow production, resulting in single cytopenias or pancytopenia [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron deficiency, which has been reported to cause both thrombocytosis and thrombocytopenia, appears to impair a late stage of thrombopoiesis [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Bone marrow failure or infiltration</span><span class="headingEndMark"> — </span>Pancytopenia is the combination of anemia, leukopenia (low white cell count), and thrombocytopenia. Its presence suggests general bone marrow dysfunction (due to infection, aplastic anemia, chemotherapeutic agents, or radiation) or infiltrative disease (leukemia, lymphoma, fibrosis, hemophagocytic lymphohistiocytosis). (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a> and  <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p>Patients with pancytopenia, especially with systemic signs and symptoms (eg, fever, weight loss, or decreased energy), should undergo prompt evaluation for a serious disorder, such as leukemia or aplastic anemia, that may require urgent intervention. The assessment usually includes bone marrow examination. (See  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia", section on 'Bone marrow examination'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Inherited platelet disorders</span><span class="headingEndMark"> — </span>Thrombocytopenia may be a presenting finding in certain rare inherited diseases, some of which also feature impaired platelet function  (<a class="graphic graphic_table graphicRef114582" href="/z/d/graphic/114582.html" rel="external">table 3</a>) [<a href="#rid17">17-21</a>]. These conditions should be considered in patients with "refractory immune thrombocytopenia (ITP)," a family history of thrombocytopenia or leukemia, or if platelet counts have been low on numerous occasions throughout the child's life.</p><p>Although less common than acquired causes of thrombocytopenia, inherited thrombocytopenias are an important consideration in children who present with isolated thrombocytopenia. Many of these syndromes are associated with other abnormalities (eg, immunodeficiency, renal disease, sensorineural hearing loss, risk of malignancy). Accurate diagnosis is also important for genetic counseling and to avoid inappropriate interventions (eg, splenectomy for presumed ITP). Historical platelet counts from children and their parents and ascertainment of the duration of bleeding symptoms, as well as identification of associated findings on history or physical, can help distinguish between inherited and acquired causes.</p><p>Most inherited platelet disorders arise from genetic defects of the megakaryocyte lineage that result in dysregulated thrombopoiesis. The number of genetic variants that have been reported to be associated with thrombocytopenia is large and growing [<a href="#rid22">22</a>].</p><p>The following sections outline some of the more common genetic syndromes associated with thrombocytopenia according to platelet size  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 2</a>). Additional information regarding inherited platelet disorders is presented separately. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>.)</p><p class="headingAnchor" id="H515229361"><span class="h3">Small platelets</span><span class="headingEndMark"> — </span>Wiskott-Aldrich syndrome (WAS) and the related disorder, X-linked thrombocytopenia (XLT), are characterized by small platelets:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>WAS </strong>– WAS is of particular importance to the pediatric health care provider because of its association with serious infections due to immune deficiency beginning in infancy or early childhood. WAS is an X-linked recessive disorder in which patients have moderate to severe thrombocytopenia with small platelets (3 to 5 fL, as compared with normal platelet size of 7 to 10 fL), severe eczema, immunodeficiency, and predisposition to malignancy. WAS can also cause ITP secondary to related immune dysregulation, so normal or large platelet size in an otherwise consistent clinical picture should not dissuade the clinician from testing for WAS. The diagnosis can be confirmed by genetic testing. (See  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>XLT</strong> – XLT, also due to a mutation in the WAS gene, presents as isolated microthrombocytopenia. Unlike WAS, XLT is not associated with eczema, recurrent infections, or predisposition to cancer. It is often difficult to differentiate WAS from XLT in young children. This determination should not be made until after the age of two years as clinical manifestations can evolve. The clinical phenotype can also vary within a family. Testing for the WAS protein levels can be helpful in that an absence of protein infers a more severe phenotype [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'X-linked thrombocytopenia'</a>.)</p><p></p><p class="bulletIndent1">XLT is distinct from "XLT with dyserythropoiesis," which is caused by mutations in t<em>he GATA1</em> gene and is characterized by large rather than small platelets, as discussed below. (See <a class="local">'Large or giant platelets'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong> – Thrombocytopenia with small platelet size has also been reported in individuals with variants in the <em>FYB, PTPRI, </em>and <em>ARPCIB</em> genes.</p><p></p><p class="headingAnchor" id="H515229456"><span class="h3">Normal-sized platelets</span><span class="headingEndMark"> — </span>Causes of inherited platelet disorders associated with thrombocytopenia and normal-sized platelets include inherited bone marrow syndromes, thrombocytopenia with absent radii (TAR) syndrome, amegakaryocytic thrombocytopenia with radioulnar synostosis (ATRUS), and familial platelet disorder with predisposition to myeloid malignancy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited bone marrow failure syndromes</strong> – Patients with inherited bone marrow syndromes (eg, Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, congenital amegakaryocytic thrombocytopenia [CAMT]) may present with isolated thrombocytopenia early in life. Other features of these syndromes include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fanconi anemia</strong> – Macrocytic anemia, short stature, hyper- or hypopigmented skin lesions, thumb and/or radial abnormalities  (<a class="graphic graphic_table graphicRef71159" href="/z/d/graphic/71159.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dyskeratosis congenita</strong> – Abnormal skin pigmentation, dystrophic nails, oral leukoplakia  (<a class="graphic graphic_table graphicRef81497" href="/z/d/graphic/81497.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Shwachman-Diamond syndrome</strong> – Neutropenia, macrocytic anemia, exocrine pancreatic dysfunction, bony abnormalities, including thoracic dystrophy with short stature. (See  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital amegakaryocytic thrombocytopenia (CAMT)</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604498&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqlnKJwgtf6%2FOE%2FXY3UroWx&amp;TOPIC_ID=5921" target="_blank">CAMT</a> presents in the newborn period with isolated severe thrombocytopenia and bleeding into the skin, mucous membranes, or gastrointestinal tract. Pancytopenia develops later in childhood. CAMT is not associated with skeletal abnormalities, which differentiates it from other inherited bone marrow failure syndromes, TAR, and ATRUS. CAMT is caused by mutations in <em>MPL</em>, which encodes the thrombopoietin receptor [<a href="#rid24">24</a>]. Bone marrow examination reveals absent or decreased megakaryocytes. The diagnosis can be confirmed by genetic testing. The only curative option is allogeneic hematopoietic cell transplantation (HCT) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TAR syndrome</strong> – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F274000&amp;token=O25AxH2ZrpTPG8o%2BGEGTWOXgFxmaxWPMO9Y7FPMiYwOQq4NOdQ7%2BUpQHPHAUl98G&amp;TOPIC_ID=5921" target="_blank">TAR syndrome</a> is associated with radial agenesis, as well as other upper and lower limb defects. Approximately half of affected individuals have associated cow's milk intolerance. Bone marrow examination usually shows absent or markedly decreased megakaryocytes with normal erythroid and myeloid maturation. It is caused by variants in the <em>RBM8A</em> gene. Affected patients usually require frequent platelet transfusions in early infancy but then show spontaneous improvement in the platelet count throughout childhood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATRUS</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605432&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypD7y8NiYYd%2BudDoEntDqSz&amp;TOPIC_ID=5921" target="_blank">ATRUS</a> is characterized by moderate to severe thrombocytopenia present at birth accompanied by proximal fusion of the radius and ulna, leading to impaired forearm pronation and supination. Additional features include clinodactyly, syndactyly, hip dysplasia, and sensorineural hearing loss. Initially, bone marrow examination shows normal cellularity with decreased megakaryocytes but may progress to hypocellularity and pancytopenia. It is caused by variants in the <em>HOX11</em> gene. In contrast to TAR syndrome, the thrombocytopenia persists with age. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other inherited thrombocytopenias predisposing to hematologic malignancy</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F188000&amp;token=tEpDslnpc0F0kICl%2Fz7sFXxTtDrQ8uhb%2FIsv0F895nenk3faUfDCT0iEXvyFbg4L&amp;TOPIC_ID=5921" target="_blank">Thrombocytopenia 2</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F616216&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4%2BZ6PRj78krCXSvwQ2%2Fv4g&amp;TOPIC_ID=5921" target="_blank">thrombocytopenia 5</a>, and familial platelet disorder with associated myeloid malignancy (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601399&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkGInmT0st2NY65P9c8uaP&amp;TOPIC_ID=5921" target="_blank">FPDMM</a>) are autosomal dominant disorders characterized by decreased platelet counts and predisposition to hematologic malignancies [<a href="#rid18">18,20,26</a>]. They are caused by germline mutations in the <em>ANKRD26</em>, <em>ETV6</em>, and <em>RUNX1</em> genes, respectively. (See  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial platelet disorder with propensity to myeloid malignancies (FPD)'</a>.)</p><p></p><p class="headingAnchor" id="H433560505"><span class="h3">Large or giant platelets</span><span class="headingEndMark"> — </span>The rare giant platelet disorders are characterized by low platelet counts and giant platelets (macrothrombocytopenia). Platelets are significantly larger than in ITP (&gt;12.4 fL and mean platelet diameter &gt;3.3 micron), with some larger than red cells  (<a class="graphic graphic_picture graphicRef102598" href="/z/d/graphic/102598.html" rel="external">picture 2</a>) [<a href="#rid27">27</a>]. Because of their large size, platelets may not be recognized by the laboratory particle counter, which may result in a falsely low reported platelet count and inaccurate calculation of the mean platelet volume.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bernard-Soulier syndrome</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F231200&amp;token=tEpDslnpc0F0kICl%2Fz7sFQJ0cbFqQ2rqnHzdjc4VeV1hEzF2h2sDbv%2Bfl9k63snE&amp;TOPIC_ID=5921" target="_blank">Bernard-Soulier syndrome</a> (BSS) is an autosomal recessive disorder characterized by mild thrombocytopenia, giant platelets (mean diameter of 5 to 6 microns), marked platelet dysfunction, and, often, severe bleeding. The bleeding may be disproportionately severe relative to the degree of thrombocytopenia. This is explained by dysfunction or absence of the platelet glycoprotein (GP) Ib-IX-V, the platelet receptor for von Willebrand factor. Symptoms include easy bruising and severe hemorrhage at the time of injury or surgery. Bone marrow evaluation often shows a hypercellular marrow despite peripheral thrombocytopenia. If suspected, the diagnosis can be confirmed by platelet aggregation testing showing a lack of response to ristocetin, flow cytometry for the GP Ib-IX-V glycoprotein, or genetic testing for the responsible mutations in the <em>GPIBA</em>, <em>GIPBB</em>, and <em>GPIX</em> genes. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Bernard-Soulier syndrome'</a>.)</p><p></p><p class="bulletIndent1">The heterozygous carrier state for BSS can be associated with macrothrombocytopenia with mild or no clinical symptoms and normal platelet function [<a href="#rid28">28,29</a>]. It is seen primarily in the Mediterranean region but also in other areas. This mild form of BSS is similar to the macrothrombocytopenia seen in DiGeorge syndrome. The chromosomal region affected in DiGeorge syndrome (22q11) encompasses the gene for one of the four subunits of the (GP) Ib-IX-V complex [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MYH9-related disorders</strong> – Mutations of the nonmuscle myosin heavy chain gene, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F160775&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313XjsYlI2vS%2BWmUWtQojHMYi&amp;TOPIC_ID=5921" target="_blank"><i>MYH9</i></a>, result in hereditary macrothrombocytopenia. These were previously described as four distinct disorders (May-Hegglin anomaly and Fechtner, Epstein, and Sebastian syndromes) but are now considered together as the spectrum of MYH9-related disorders [<a href="#rid31">31</a>]. They are characterized by macrothrombocytopenia, variable appearance of leukocyte inclusions, and other abnormalities, including sensorineural hearing loss, cataracts, and nephritis [<a href="#rid32">32,33</a>]. The risk for extra-hematologic manifestations (nephropathy and deafness) is correlated with the specific <em>MYH9</em> mutation [<a href="#rid34">34</a>]. Lack of a relevant family history does not rule out the disorder, because approximately one-third of mutations are sporadic. MYH9-related disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'MYH9-related disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paris-Trousseau syndrome</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F188025&amp;token=tEpDslnpc0F0kICl%2Fz7sFXxTtDrQ8uhb%2FIsv0F895nc4md64h%2F76vzuEGvcegVCa&amp;TOPIC_ID=5921" target="_blank">Paris-Trousseau syndrome</a> is a rare condition with mild to moderate thrombocytopenia and large platelets with giant alpha granules. Depending on the size of the underlying genetic lesion (involving the <em>FLI1</em> gene on chromosome 11q23), intellectual disability; head and face dysmorphisms; and cardiac, renal, and gastrointestinal defects can also be present. (See  <a class="medical medical_review" href="/z/d/html/16660.html" rel="external">"Microdeletion syndromes (chromosomes 1 to 11)", section on '11q24.1 deletion syndrome (Jacobsen syndrome)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gray platelet syndrome</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F139090&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiumIF2uWUifAn83bIUK8NusI&amp;TOPIC_ID=5921" target="_blank">Gray platelet syndrome</a> is a rare autosomal recessive disorder characterized by moderate thrombocytopenia, mild to moderate bleeding tendency, and marked decrease or absence of platelet alpha granules. The platelets are enlarged, but not giant, and have a gray appearance on peripheral blood smears. Many patients with gray platelet syndrome develop stable myelofibrosis associated with progressive thrombocytopenia. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Gray platelet syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>XLT with dyserythropoiesis</strong> – X-linked disorders of thrombocytopenia and dyserythropoiesis are due to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F305371&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6F4%2BYIZmRJWvRjw4VyFmeb1&amp;TOPIC_ID=5921" target="_blank"><i>GATA1</i></a> mutations on the X chromosome. They are characterized by severely defective maturation of megakaryocytes, alpha granule deficiency, abnormalities of the cytoplasmic membrane, mild dyserythropoiesis, and red cell hemolysis [<a href="#rid35">35,36</a>]. They should be suspected in boys with inherited thrombocytopenia, abnormal red cell morphology, and a hypercellular bone marrow. Patients with the <em>GATA1</em> Arg216 mutation also have a thalassemic phenotype with associated microcytosis [<a href="#rid36">36</a>]. These conditions have been variably termed "XLT with thalassemia," "XLT with dyserythropoiesis," or "X-linked gray platelet syndrome" [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant deafness with thrombocytopenia</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F124900&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TP1%2BhN6B2F65H0PV9IhzPC&amp;TOPIC_ID=5921" target="_blank">Autosomal dominant deafness with thrombocytopenia</a> is caused by mutation in the <em>DIAPH1 </em>gene. It is characterized by sensorineural hearing loss within the first decade of life, mild to moderate thrombocytopenia, and large platelets. Functional studies have demonstrated altered platelet cytoskeletal regulation and proplatelet formation [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sitosterolemia</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F210250&amp;token=tEpDslnpc0F0kICl%2Fz7sFZpszKvOtG3bo7mRUx02%2BlYZ2LJHsE75hWeWc23JUurP&amp;TOPIC_ID=5921" target="_blank">Sitosterolemia</a> (alternatively termed "phytosterolemia") is an autosomal recessive metabolic condition caused by mutations in the <em>ABCG8</em> or <em>ABCG5</em> genes. It is characterized by hyperabsorption of cholesterol and plant sterols from the intestine. Typical features include very high plasma cholesterol levels, tendon and tuberous xanthomas, and atherosclerotic complications (ie, premature coronary artery disease). Hematologic abnormalities, including stomatocytosis and macrothrombocytopenia, have been described in some patients with this disorder, particularly in patients of Mediterranean descent. The hematologic findings in these patients appear to be due to abnormal lipid content in red blood cell and platelet membranes caused by extremely high plasma levels of phytosterols from high dietary consumption of olive oil.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTN1-related macrothrombocytopenia</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615193&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4oM2N5pvDDaG4Ml1fCOb7e&amp;TOPIC_ID=5921" target="_blank">ACTN1-related macrothrombocytopenia</a> is an autosomal dominant form of macrothrombocytopenia. Affected patients usually have no or only mild bleeding tendency. Laboratory studies show decreased numbers of large platelets and anisocytosis (ie, a broad distribution of platelet size), but in vitro functional platelet testing is typically normal. This disorder is also characterized by an elevated immature platelet fraction and can be confused with ITP [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Thrombocytopenia is defined as a platelet count &lt;150,000/microL. It is clinically suspected when there is a history of easy bruising or bleeding, or it may present as an incidental finding during routine evaluation or during laboratory investigations performed for other reasons. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification schemas</strong> – Causes of thrombocytopenia can be classified according to (see <a class="local">'Classification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanism – Increased destruction (including sequestration and pooling of platelets), dilutional, or decreased production  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 1</a>). (See <a class="local">'Platelet destruction'</a> above and <a class="local">'Impaired platelet production'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet size – Large (mean platelet volume [MPV] &gt;11 fL), normal (MPV 7 to 11 fL), and small (MPV &lt;7 fL). This classification schema is especially useful when platelet sizes are extreme. Large or giant platelets suggest immune-mediated thrombocytopenia or one of the giant platelet disorders, while very small platelets are almost exclusively found in Wiskott-Aldrich syndrome (WAS) or X-linked thrombocytopenia (XLT)  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mode of acquisition – Acquired or inherited.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Degree of the thrombocytopenia – Mild to moderate thrombocytopenia (&gt;20,000/microL) or severe thrombocytopenia (&lt;20,000/microL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of platelet destruction</strong> – Destructive mechanisms include  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 1</a>) (see <a class="local">'Platelet destruction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immune-mediated destruction (eg, immune thrombocytopenia [ITP]) (see <a class="local">'Immune thrombocytopenia'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drug-induced thrombocytopenia (see <a class="local">'Drug-induced thrombocytopenia'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet activation and consumption, including (see <a class="local">'Platelet activation and consumption'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Disseminated intravascular coagulation and the thrombotic microangiopathies (thrombotic thrombocytopenic purpura [TTP], Shiga toxin-mediated hemolytic uremic syndrome [ST-HUS], and complement-mediated hemolytic uremic syndrome [CM-HUS])</p><p class="bulletIndent3"><span class="glyph">-</span>Major surgery or trauma</p><p class="bulletIndent3"><span class="glyph">-</span>Kasabach-Merritt phenomenon</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical platelet destruction (use of extracorporeal therapies, such as extracorporeal membrane oxygenation and cardiopulmonary bypass) (see <a class="local">'Mechanical destruction'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platelet sequestration and trapping (eg, due to hypersplenism) (see <a class="local">'Sequestration and trapping'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dilutional </strong>– Thrombocytopenia in the setting of massive red cell transfusions. (See <a class="local">'Dilutional'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of impaired platelet production</strong> – Decreased production of platelets may be due to bone marrow infiltration, suppression, or failure or a defect in megakaryocyte development and differentiation. Causes include  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 1</a>) (see <a class="local">'Impaired platelet production'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection (see <a class="local">'Infection'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional deficiencies (see <a class="local">'Nutritional deficiencies'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Leukemia, lymphoma, or other bone marrow-infiltrating disease (see <a class="local">'Bone marrow failure or infiltration'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Acquired or inherited aplastic anemia or other bone marrow failure syndrome (see <a class="local">'Bone marrow failure or infiltration'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic disorders  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 2</a>) (see <a class="local">'Inherited platelet disorders'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes</strong> – Thrombocytopenia may be a presenting finding in certain rare inherited diseases, some  (<a class="graphic graphic_table graphicRef61163" href="/z/d/graphic/61163.html" rel="external">table 1</a>) of which also feature impaired platelet function  (<a class="graphic graphic_table graphicRef89962" href="/z/d/graphic/89962.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef114582" href="/z/d/graphic/114582.html" rel="external">table 3</a>). These conditions should be considered in patients with "refractory ITP," a family history of thrombocytopenia or leukemia, or if platelet counts have been low on numerous occasions throughout the child's life. Accurate diagnosis is important for genetic counseling to avoid inappropriate interventions (eg, splenectomy for presumed ITP) and because many of these syndromes are associated with other abnormalities (eg, immunodeficiency, renal disease, sensorineural hearing loss, risk of malignancy). Historical platelet counts from children and their parents and ascertainment of the duration of bleeding symptoms can help distinguish between inherited and acquired causes. (See <a class="local">'Inherited platelet disorders'</a> above and  <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">"Approach to the child with unexplained thrombocytopenia", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H3938779224"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald Yee, MD, and Jenny Despotovic DO, MS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013; 60 Suppl 1:S12.</a></li><li><a class="nounderline abstract_t">Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019; 134:9.</a></li><li><a class="nounderline abstract_t">Rotz SJ, Ware RE, Kumar A. Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatr Blood Cancer 2018; 65:e27260.</a></li><li><a class="nounderline abstract_t">Avila ML, Shah V, Brandão LR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost 2013; 11:660.</a></li><li><a class="nounderline abstract_t">Takemoto CM, Streiff MB. Heparin-induced thrombocytopenia screening and management in pediatric patients. Hematology Am Soc Hematol Educ Program 2011; 2011:162.</a></li><li><a class="nounderline abstract_t">Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica 2022; 107:1264.</a></li><li><a class="nounderline abstract_t">Pérez-Rodríguez A, Lourés E, Rodríguez-Trillo Á, et al. Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review. Thromb Res 2014; 134:1171.</a></li><li><a class="nounderline abstract_t">Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010; 2010:135.</a></li><li><a class="nounderline abstract_t">Thiele T, Selleng K, Selleng S, et al. Thrombocytopenia in the intensive care unit-diagnostic approach and management. Semin Hematol 2013; 50:239.</a></li><li><a class="nounderline abstract_t">Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11:249.</a></li><li><a class="nounderline abstract_t">Karam O, Tucci M. Massive Transfusion in Children. Transfus Med Rev 2016; 30:213.</a></li><li><a class="nounderline abstract_t">Hashimoto H, Maruyama H, Fujimoto K, et al. Hematologic findings associated with thrombocytopenia during the acute phase of exanthem subitum confirmed by primary human herpesvirus-6 infection. J Pediatr Hematol Oncol 2002; 24:211.</a></li><li><a class="nounderline abstract_t">La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol 1995; 8:249.</a></li><li><a class="nounderline abstract_t">Giustozzi M, Ehrlinder H, Bongiovanni D, et al. Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment. Blood Rev 2021; 50:100864.</a></li><li><a class="nounderline abstract_t">Torrez M, Chabot-Richards D, Babu D, et al. How I investigate acquired megaloblastic anemia. Int J Lab Hematol 2022; 44:236.</a></li><li><a class="nounderline abstract_t">Perlman MK, Schwab JG, Nachman JB, Rubin CM. Thrombocytopenia in children with severe iron deficiency. J Pediatr Hematol Oncol 2002; 24:380.</a></li><li><a class="nounderline abstract_t">Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390.</a></li><li><a class="nounderline abstract_t">Kumar R, Kahr WH. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematol Oncol Clin North Am 2013; 27:465.</a></li><li><a class="nounderline abstract_t">Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost 2013; 11:1006.</a></li><li><a class="nounderline abstract_t">Melazzini F, Zaninetti C, Balduini CL. Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias. Haemophilia 2017; 23:673.</a></li><li><a class="nounderline abstract_t">Favier R, Raslova H. Progress in understanding the diagnosis and molecular genetics of macrothrombocytopenias. Br J Haematol 2015; 170:626.</a></li><li><a class="nounderline abstract_t">Lambert MP. Updates in diagnosis of the inherited platelet disorders. Curr Opin Hematol 2020; 27:333.</a></li><li><a class="nounderline abstract_t">Rivers E, Worth A, Thrasher AJ, Burns SO. How I manage patients with Wiskott Aldrich syndrome. Br J Haematol 2019; 185:647.</a></li><li><a class="nounderline abstract_t">Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139.</a></li><li><a class="nounderline abstract_t">King S, Germeshausen M, Strauss G, et al. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005; 131:636.</a></li><li class="breakAll">Deuitch N, Broadbridge E, Cunningham L, Liu P.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Noris P, Klersy C, Zecca M, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7:2131.</a></li><li><a class="nounderline abstract_t">Savoia A, Balduini CL, Savino M, et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97:1330.</a></li><li><a class="nounderline abstract_t">Bragadottir G, Birgisdottir ER, Gudmundsdottir BR, et al. Clinical phenotype in heterozygote and biallelic Bernard-Soulier syndrome--a case control study. Am J Hematol 2015; 90:149.</a></li><li><a class="nounderline abstract_t">Van Geet C, Devriendt K, Eyskens B, et al. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998; 44:607.</a></li><li><a class="nounderline abstract_t">Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82:203.</a></li><li><a class="nounderline abstract_t">Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005; 130:620.</a></li><li><a class="nounderline abstract_t">Han KH, Lee H, Kang HG, et al. Renal manifestations of patients with MYH9-related disorders. Pediatr Nephrol 2011; 26:549.</a></li><li><a class="nounderline abstract_t">Pecci A, Panza E, Pujol-Moix N, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29:409.</a></li><li><a class="nounderline abstract_t">Del Vecchio GC, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol 2005; 114:113.</a></li><li><a class="nounderline abstract_t">Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100:2040.</a></li><li><a class="nounderline abstract_t">Balduini CL, De Candia E, Savoia A. Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia" rather than "X-linked gray platelet syndrome". Blood 2007; 110:2770.</a></li><li><a class="nounderline abstract_t">Stritt S, Nurden P, Turro E, et al. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood 2016; 127:2903.</a></li><li><a class="nounderline abstract_t">Boutroux H, David B, Guéguen P, et al. ACTN1-related Macrothrombocytopenia: A Novel Entity in the Progressing Field of Pediatric Thrombocytopenia. J Pediatr Hematol Oncol 2017; 39:e515.</a></li></ol></div><div id="topicVersionRevision">Topic 5921 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109501" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940614" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29856527" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350790" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Systematic review on heparin-induced thrombocytopenia in children: a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Heparin-induced thrombocytopenia screening and management in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35642486" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of drug-induced immune thrombocytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242241" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239783" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thrombocytopenia in the intensive care unit patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953341" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thrombocytopenia in the intensive care unit-diagnostic approach and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3901259" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27287298" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Massive Transfusion in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990308" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hematologic findings associated with thrombocytopenia during the acute phase of exanthem subitum confirmed by primary human herpesvirus-6 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7663049" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mechanisms of dengue virus-induced bone marrow suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217531" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34981651" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : How I investigate acquired megaloblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142787" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombocytopenia in children with severe iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504084" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inherited thrombocytopenia: when a low platelet count does not mean ITP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23714308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23510089" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inherited thrombocytopenias frequently diagnosed in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28594466" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944497" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Progress in understanding the diagnosis and molecular genetics of macrothrombocytopenias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701615" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Updates in diagnosis of the inherited platelet disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30864154" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How I manage patients with Wiskott Aldrich syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133753" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16351641" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16351641" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740094" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222377" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25370924" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical phenotype in heterozygote and biallelic Bernard-Soulier syndrome--a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773854" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792306" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098078" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genotype-phenotype correlation in MYH9-related thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210153" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Renal manifestations of patients with MYH9-related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059020" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103636" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200364" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17881640" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia" rather than "X-linked gray platelet syndrome".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26912466" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562514" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ACTN1-related Macrothrombocytopenia: A Novel Entity in the Progressing Field of Pediatric Thrombocytopenia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
